Table 2.
The influence of significant covariates individually and in combination on the apparent clearance of oxypurinol
| Between subject variability (%) | Proportional error (%) | Likelihood ratio | |
|---|---|---|---|
| Base model | 65 | 21.7 | 3296 |
| rs1165196 polymorphism in SLC17A1 | 40 | 16.7 | 3291 |
| rs16890979 polymorphism in SLC2A9 | 36 | 16.7 | 3345 |
| CLCr | 39 | 13.7 | 3054 |
| CLCr+ rs16890979 polymorphism in SLC2A9 | 36 | 13.6 | 3162 |
| CLCr+ diuretic use | 31 | 13.4 | 3022 |
| CLCr+ diuretic use + probenecid use* | 28 | 13.3 | 3004 |
| CLCr+ diuretic use + probenecid use + gender | 27 | 13.2 | 2996 |
| CLCr+ diuretic use + probenecid use + gender + age | 27 | 13.1 | 2987 |
CLCr, estimated creatinine clearance using Cockcroft-Gault equation with lean body weight; *Final covariate model.